Stockscreener 앱 받기
32.88
0.83%
0.27
시간 외 거래:
32.06
-0.82
-2.49%
전일 마감가:
$32.61
열려 있는:
$32.58
하루 거래량:
185.27K
Relative Volume:
0.70
시가총액:
$1.65B
수익:
$345.60M
순이익/손실:
$-79.01M
주가수익비율:
-20.49
EPS:
-1.6045
순현금흐름:
$-18.62M
1주 성능:
-0.36%
1개월 성능:
+11.46%
6개월 성능:
-17.18%
1년 성능:
-54.52%
1일 변동 폭
$31.76
$33.60
1주일 범위
$31.16
$33.93
52주 변동 폭
$27.69
$76.98
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
IMCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
32.88 | 1.65B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade - Yahoo Finance
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - Zacks Investment Research
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer - Yahoo Finance
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa
Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com
Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance
New Strong Buy Stocks for December 12th - Yahoo Finance
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
SNTI Stock Skyrockets On Initial Data From Phase I Cancer Study - Barchart
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - Yahoo Finance
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
Stack Capital Group announces normal course issuer bid - MSN
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
What will it take for small caps to finally outperform large caps on earnings, performance? - MSN
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart
Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Immunocore repays Pharmakon loan, ends agreement - Investing.com India
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart
Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India
Immunocore shares maintain buy rating on HIV treatment potential - Investing.com
Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... - Yahoo Finance
Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com
Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK
Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex
Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com
TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India
Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex
Immunocore Holdings plc ADR (IMCR) is looking forward to a strong quarter - SETE News
Immunocore stock hits 52-week low at $32.84 amid market challenges - Investing.com
Ratios Revealed: Decoding Immunocore Holdings plc ADR (IMCR)’s Financial Health - The Dwinnex
Have you been able to find a good deal on Immunocore Holdings plc ADR’s shares? - US Post News
Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds - Yahoo Finance UK
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):